Molecular Imaging News and Research

RSS

Research project to develop new high-precision radiology system for COVID-19

Universidad Carlos III de Madrid is participating in a research project together with the Hospital General Universitario Gregorio Marañón, the Instituto de Investigación Sanitaria San Carlos and the company Sedecal Molecular Imaging, project coordinator, to develop a new high-precision radiology system for coronavirus pulmonary involvement.

15 Apr 2020

Global nuclear medicine community shares approaches to contain the spread of COVID-19

In an effort to provide safer working environments for nuclear medicine professionals and their patients, clinics across five continents have shared their approaches to containing the spread of COVID-19 in a series of editorials, published ahead of print in The Journal of Nuclear Medicine.

1 Apr 2020

Total-body PET provides suitable images of antibodies up to 30 days after injection

Combining 89Zr-labeled antibodies with total-body positron emission tomography (PET) has extended the utility of novel total-body PET scanners, providing suitable images up to 30 days after the initial injection.

31 Mar 2020

Novel PET/CT systems provide quantitative assessment of brain stem nuclei in patients with hearing loss

Novel, fully digital, high-resolution positron emission tomography/computed tomography (PET/CT) imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment, according to a new study published in the March issue of The Journal of Nuclear Medicine.

25 Mar 2020

PET imaging helps researchers to detect transplant patients with cardiac allograft vasculopathy

Myocardial blood flow and myocardial flow reserve have been identified as accurate indicators for graft failure after cardiac transplantation, according to a new study published in The Journal of Nuclear Medicine.

5 Mar 2020

Researchers identify major landmarks of peripheral artery disease recovery

Novel biomedical advances that show promise in the lab often fall short in clinical trials. For researchers studying peripheral artery disease, this is made more difficult by a lack of standardized metrics for what recovery looks like.

2 Mar 2020

New radiopharmaceutical could aid in more accurate diagnosis of neuroendocrine tumor metastases

The newly developed [55Co]55Co-DOTATATE imaging agent has emerged as a more accurate and sensitive radiopharmaceutical to aid in the diagnosis of neuroendocrine tumor metastases.

27 Feb 2020

Revolutionary SPion technology enables remote analysis with mass spectrometry

Trace Matters Scientific today introduced SPion -a revolutionary technology that enables the world's most sensitive and versatile remote analysis with mass spectrometry.

16 Feb 2020

Purdue-developed 'fluorescent markers' begin Phase 3 clinical trials

On Target Laboratories Inc., a privately held biotechnology company developing the use of Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26% of patients undergoing pulmonary resection for non-small-cell lung cancer.

6 Feb 2020

MR Solutions installs 3T PET-MR system at Western University’s ImPaKT facility

MR Solutions has installed a 3T PET-MR preclinical imaging system at Western University’s one of a kind ImPaKT Laboratory in Ontario.

From MR Solutions 5 Feb 2020

Study suggests potential therapy option for early-stage breast cancer

Radionuclide therapy has proven successful in delaying the growth of disseminated tumor cells (DTCs) in early-stage breast cancer in a small animal model, suggesting its use as a potential adjuvant therapy for retarding the proliferation of DTCs.

5 Feb 2020

Do biologists and physicists approach AFM differently?

This was the question at the forefront of my mind as I attended the Linz Winter Workshop back in February. Do biologists and physicists approach AFM differently and, does it matter?

From Nu Nano Ltd 28 Jan 2020

New technology enhances visualization of lung cancer tissue, helps improve patient outcomes

A groundbreaking tumor-highlighting technology- OTL38- enhances the visualization of lung cancer tissue, providing surgeons with a significantly better chance of finding and removing more cancer than previously possible, according to a scientific presentation at the 56th Annual Meeting of The Society of Thoracic Surgeons.

27 Jan 2020

PET/MRI identifies potentially useful breast cancer biomarkers

Researchers have identified several potentially useful breast cancer biomarkers that indicate the presence and risk of malignancy, according to new research published in the January issue of The Journal of Nuclear Medicine.

22 Jan 2020

PENTAX Medical secures CE mark approval for innovative AI-assisted polyp detector

PENTAX Medical, a division of the HOYA Group, announced that it has cleared CE mark for DISCOVERY, an innovative Artificial Intelligence assisted polyp detector designed to support endoscopists in finding potential polyps during a colorectal examination.

From PENTAX Medical Company 10 Jan 2020

Administering enzalutamide results in significant increase in PSMA density on tumor surface

When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewhat remote, rather idealistic genius sitting alone in their room or laboratory and somehow discovering the most amazing things without every having contact with the 'normal' world.

9 Jan 2020

Bacterial exposure is a potential environmental risk factor in developing coeliac disease

Bacterial exposure has been identified as a potential environmental risk factor in developing coeliac disease, a hereditary autoimmune-like condition that affects about one in 70 Australians.

8 Jan 2020

New radiotracer can provide insights into how the heart recovers after myocardial infarction

Insights into how the heart recovers after myocardial infarction (heart attack) can be obtained with a new radiotracer that targets fibroblast activity prior to it causing permanent damage.

2 Jan 2020

Tau-protein better predicts brain atrophy in Alzheimer's patients than amyloid plaques

Brain imaging of pathological tau-protein "tangles" reliably predicts the location of future brain atrophy in Alzheimer's patients a year or more in advance, according to a new study by scientists at the UC San Francisco Memory and Aging Center. In contrast, the location of amyloid "plaques," which have been the focus of Alzheimer's research and drug development for decades, was found to be of little utility in predicting how damage would unfold as the disease progressed.